Search filters
Filters
Clear All

Phase

  • 54
  • 61
  • 2
  • 53
  • 1
  • 51
  • 11
  • 670
  • 926
  • 606
  • 5
  • 39
  • 886

Found 930 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Compassionate Use of ASTX295 in an Individual Patient with Dedifferentiated Liposarcoma Cancer

99 years and younger
All genders
See Attached Submission Documents See Attached Submission Documents See Attached Submission Documents
Learn More

UPCC 28424 Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel

99 years and younger
All genders
The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release. We would like to rely on Advarra IRB as the IRB of record for this study.
Learn More

PHIN-001

99 years and younger
All genders
Please see section 2 of the protocol, under "Introduction" for a list of study objectives. Please see section 2 of the protocol, under "Objectives" for a list of primary outcome variables. Please see section 2 of the protocol, under "Objectives" for a list of secondary outcome variables.
Learn More

Radiomics Tool for Pulmonary Nodule Risk Stratification

99 years and younger
All genders
The objective of this pragmatic clinical trial is to determine the real-world effect of a radiomics-based computer-aided diagnosis tool on pulmonary nodule management decisions. We hypothesize that a higher proportion of pulmonary nodules will be appropriately managed when clinicians prospectively use a CAD-based risk stratification strategy to evaluate pulmonary nodules. …
Learn More

uniQure

99 years and younger
All genders
Observation Period: Primary objectives: To observe and characterize seizure frequency via study-specific electronic seizure diaries in adults with unilateral refractory MTLE. condary: -To observe and characterize electroencephalogram (EEG) via 48-hour EEG recording. -To observe and characterize patient-reported outcomes (PROs). B) Evaluation Period Primary: To evaluate the safety and tolerability of …
Learn More

UPCC 03921: A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

99 years and younger
All genders
Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives) Please refer to Section 2 of the full protocol (Study Objectives)
Learn More

UPCC 32424: An Open-Label, Expanded Access Program of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease in Participants Who Have Received at Least 2 Lines of Systemic Therapy

99 years and younger
All genders
To provide axatilimab through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for axatilimab in the treatment of GVHD. We would like to rely on Advarra as the …
Learn More

App-delivered Exposure and Response Prevention for Obsessive-Compulsive Disorder (BOLD – Beating OCD and Learning Digitally) (BOLD)

18-65 years
All genders
This study will provide the first test of a  therapist-supported treatment app for adults with obsessive-compulsive disorder. Participants will get free access to the app and 7 free 30-minute sessions with a therapist from the Center for the Treatment and Study of Anxiety. The study also includes electronic surveys and …
Learn More

The SAK HFpEF Trial

99 years and younger
All genders
1.Compare the impact on submaximal exercise endurance of Empa, with and without KNO3, as compared to active control (Potassium Chloride, KCl).2.Assess the impact of Empa, with and without KNO3, on SkM OxPhos using novel in vivo MRI-based imaging techniques that quantify SkM OxPhos and intramuscular perfusion with exercise3.Assess the impact …
Learn More

UPCC 26922: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

99 years and younger
All genders
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
791 - 800 of 930